The blogger “Liberty Beats News” reported the following disturbing story. Secretary of Defense Pete Hegseth is obsessed with the idea of “lethality” and “masculinity” that leads to stories like this one, as well as bias against women, who don’t have the same levels of testosterone as men. Even without the testosterone that Hegseth demands, women seem to be capable of exemplary leadership. Hegseth, however, continues to block most women from leadership roles in the military.
Blogger Liberty Brats News reports:
Pentagon Announces Mandatory Testosterone Testing for Troops Over 30 — And the Science Behind It Is Shakier Than Hegseth Is Selling It
Defense Secretary Pete Hegseth is framing declining testosterone as a fixable threat to military “lethality,” but the medicine tells a messier story: most people prescribed testosterone therapy never get properly diagnosed first, and the FDA has flagged real cardiovascular risk
WASHINGTON — July 15, 2026
Defense Secretary Pete Hegseth announced Wednesday that all active-duty service members age 30 and older will be required to undergo annual testosterone deficiency screening as part of their existing periodic health assessment — branding the effort “The High-T Department of War” in a video posted to social media.
What Was Announced
Under the new policy, troops 30 and up will be tested annually; those under 30 can opt in voluntarily. If a service member is found to have a deficiency, testosterone replacement therapy (TRT) is offered, not mandated — the choice to actually take it remains with the individual. Hegseth framed it as a health and performance initiative: “It’s about restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight.” The Pentagon has not clarified whether the requirement or the treatment option extends to women in the military, whose testosterone levels also decline with age.
The Marketing Language vs. the Actual Medicine
Hegseth’s own phrase, “High-T,” isn’t a medical term — it’s borrowed directly from a social media fitness and masculinity trend, where influencers encourage men to chase higher testosterone numbers as a marker of strength and virility. That distinction matters, because the FDA has never approved testosterone therapy on that basis.

The only FDA-approved use for TRT is treating clinical hypogonadism — a specific, diagnosable medical condition involving genuine testicular or pituitary dysfunction, confirmed through repeated blood tests and documented symptoms. Simply having a number that’s lower than it used to be isn’t the same thing as having a treatable deficiency, and the FDA has never approved TRT as a tool for boosting combat performance, aggression, or “lethality” in men with normal age-related hormone decline.
What “Low Testosterone” Actually Means — And Doesn’t
Testosterone drops by roughly 1% a year after age 30, according to the Mayo Clinic — a completely normal, expected part of aging, not a malfunction. True testosterone deficiency, called hypogonadism, affects an estimated 5.6% of men between 30 and 79. That means the overwhelming majority of the men this policy will test every year have testosterone levels that are simply aging normally, not failing.

Testosterone Levels By Age: Normal Ranges 2026 Guide
A 2026 Endocrine Society study presented at its annual meeting found that most men who are already being prescribed testosterone therapy in civilian medicine never received proper, guideline-based diagnostic testing beforehand — meaning a huge share of current TRT patients may not actually meet the medical bar for needing it in the first place. One of the study’s independent reviewers, a reproductive endocrinologist at Imperial College London, called overprescribing “a problem of our time,” driven in part by corporate telehealth providers with minimal clinical oversight — a dynamic a mandatory military-wide testing program risks reproducing at scale.
The Risks Nobody’s Talking About in the Announcement
Testosterone therapy isn’t risk-free. The FDA issued a formal safety communication requiring TRT products to carry warning labels about a possible increased risk of heart attack and stroke. The research since then has been genuinely mixed — some large studies have found elevated cardiovascular risk in men on TRT, while others, including a comprehensive Harvard-affiliated review of 72 studies, found no compelling evidence of increased heart disease or cancer risk. What that actually means is that the cardiovascular safety of giving testosterone therapy to a large, mostly healthy population has not been settled science — which makes rolling it out across the entire U.S. military, framed as a performance and readiness initiative, a real-world experiment on hundreds of thousands of people rather than a proven intervention.
A Broader Pattern
This isn’t happening in isolation. The FDA moved in April to expand access to TRT more broadly, and Hegseth has spent his tenure building what he calls a “warrior ethos” around hyper-masculine physical standards — requiring all combat roles to meet a single “highest male standard,” warning against “fat generals and admirals,” and mocking transgender troops in public remarks.

Notably, Health and Human Services official Dr. Mehmet Oz has already publicly praised Trump’s own testosterone levels, according to RFK Jr., calling them the highest he’s seen in a man over 70 — a strange data point to have entered the public discourse days before this policy, and a reminder that “optimizing testosterone” has become as much a cultural signal in this administration as a medical one.
Bottom Line
Nothing about this policy is inherently sinister — screening for a real, underdiagnosed medical condition isn’t unreasonable on its face. What doesn’t hold up is the marketing: testosterone testing doesn’t measure “lethality,” normal aging isn’t a deficiency, and the treatment itself carries cardiovascular questions that haven’t been fully answered even in civilian medicine, where prescribing already outpaces proper diagnosis. Framing a hormone panel as the key to combat readiness sells better on social media than it does in a peer-reviewed journal.
Sources
• Forbes — “Hegseth Announces ‘Testosterone Deficiency’ Screening For Soldiers 30 And Over,” July 15, 2026. forbes.com/sites/saradorn/2026/07/15/hegseth-announces-testosterone-deficiency-screening-for-soldiers-30-and-over/
• Newsweek — “Hegseth’s New Military Testosterone Rules: Who Is On The Hook?” July 15, 2026. newsweek.com/hegseth-announces-new-required-pentagon-testosterone-tests-who-it-impacts-12200211
• NOTUS — “Testosterone-Fueled Troops? Hegseth Says Military to Begin Testing Hormones,” July 15, 2026. notus.org/defense/testosterone-troops-hegseth-testing
• Stars and Stripes — “‘High-T Department of War’: Hegseth announces annual testosterone screenings for service members age 30 or older,” July 15, 2026. stripes.com/theaters/us/2026-07-15/hegseth-approve-testosterone-testing-troops-22274442.html
• The Hill — “Pentagon to screen troops over 30 for testosterone,” July 15, 2026. thehill.com/policy/defense/5969935-hegseth-testosterone-testing-dod/
• Endocrine Society — “Testosterone therapy in men may be overprescribed, inconsistent with clinical guidelines,” June 13, 2026. endocrine.org/news-and-advocacy/news-room/2026/papaleontiou-press-release-endo-2026
• U.S. FDA Drug Safety Communication — “FDA cautions about using testosterone products for low testosterone due to aging,” fda.gov/Drugs/DrugSafety/ucm436259.htm
• Harvard Gazette — “Study finds no direct links between testosterone therapy, diseases,” Harvard Medical School review of 72 studies. news.harvard.edu/gazette/story/2004/01/study-finds-no-direct-links-between-testosterone-therapy-diseases

